Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by Biofinderon Jun 18, 2018 7:06am

234 Views

Post# 28184570

RE:RE:The Ryplazim numbers alone still are staggering to consider

Jackal5 wrote: Biofinder, I do not believe that one can use $75,000 per year for all indications of Pg. DFUs use a much diluted version of Pg and so do TMRs. PL indicated some years ago that the diluted Pg would also have a diluted price per ml.
Jackal5

You’re correct. ((For those wondering where I got the 75k, PL stated they expected revenue of $150 million from Plasminogen Deficiency (2,000 U.S. patients)). This list gives some indication of the size of the Ryplazim market. IPF, DFU, TMP, will use the diluted version like Jackal5 said.

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle